PMID- 33073050
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201020
IS  - 2415-1289 (Electronic)
IS  - 2415-1289 (Linking)
VI  - 5
DP  - 2020
TI  - Gastrointestinal cancers: current biomarkers in esophageal and gastric 
      adenocarcinoma.
PG  - 55
LID - 10.21037/tgh.2020.01.08 [doi]
LID - 55
AB  - Esophageal and gastric adenocarcinomas are frequently diagnosed at an advanced 
      stage and have a dismal prognosis. Even in patients with potentially curative 
      cancer, nearly 50% will develop recurrent disease despite aggressive treatments. 
      A number of biomarkers currently guide treatment decisions for patients with 
      esophageal and gastric adenocarcinoma and include human epidermal growth factor 
      receptor 2 (HER2) amplification, mismatch repair deficiency/microsatellite 
      instability (dMMR/MSI-H) and program death-ligand 1 (PD-L1) expression. This 
      review will focus on the function, testing and FDA-approved targeted therapies 
      for HER2, dMMR/MSI-H and PD-L1. In addition, a number of novel targets in 
      esophageal and gastric cancer are being studied in clinical trials. 
      Neurotrophic-tropomyosin receptor kinase (NTRK), claudin-18 (CLDN18)/Rho GTPase 
      activating protein 26 (ARHGAP26) gene fusion, fibroblast growth factor receptor 
      (FGFR), lymphocyte-activation gene 3 (LAG3) and T cell immunoglobulin and 
      mucin-domain containing-3 (TIM3) will be briefly reviewed. Despite several 
      biomarkers used in the selection of treatment therapies, treatment outcomes 
      remain poor. Future research efforts will focus on the identification of new 
      biomarkers, moving existing biomarkers into earlier lines of therapy, and 
      evaluating new combinations of existing biomarkers and therapies.
CI  - 2020 Translational Gastroenterology and Hepatology. All rights reserved.
FAU - Dhakras, Purabi
AU  - Dhakras P
AD  - Department of Pathology and Laboratory Medicine, University of Wisconsin, 
      Madison, WI, USA.
FAU - Uboha, Nataliya
AU  - Uboha N
AD  - Division of Hematology, Medical Oncology and Palliative Care, Department of 
      Medicine, University of Wisconsin, Madison, WI, USA.
AD  - UW Carbone Cancer Center, Madison, WI, USA.
AD  - William S. Middleton Memorial Veterans Hospital, Madison, WI, USA.
FAU - Horner, Vanessa
AU  - Horner V
AD  - Department of Pathology and Laboratory Medicine, University of Wisconsin, 
      Madison, WI, USA.
AD  - Wisconsin State Lab of Hygiene, Madison, WI, USA.
FAU - Reinig, Erica
AU  - Reinig E
AD  - Department of Pathology and Laboratory Medicine, University of Wisconsin, 
      Madison, WI, USA.
FAU - Matkowskyj, Kristina A
AU  - Matkowskyj KA
AD  - Department of Pathology and Laboratory Medicine, University of Wisconsin, 
      Madison, WI, USA.
AD  - UW Carbone Cancer Center, Madison, WI, USA.
AD  - William S. Middleton Memorial Veterans Hospital, Madison, WI, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201005
PL  - China
TA  - Transl Gastroenterol Hepatol
JT  - Translational gastroenterology and hepatology
JID - 101683450
PMC - PMC7530320
OTO - NOTNLM
OT  - Human epidermal growth factor receptor 2 (HER2)
OT  - microsatellite instability (MSI)
OT  - program death-ligand 1 (PD-L1)
COIS- Conflicts of Interest: The authors have no conflicts of interest to declare.
EDAT- 2020/10/20 06:00
MHDA- 2020/10/20 06:01
PMCR- 2020/10/05
CRDT- 2020/10/19 06:00
PHST- 2019/12/05 00:00 [received]
PHST- 2020/01/15 00:00 [accepted]
PHST- 2020/10/19 06:00 [entrez]
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2020/10/20 06:01 [medline]
PHST- 2020/10/05 00:00 [pmc-release]
AID - tgh-05-2020.01.08 [pii]
AID - 10.21037/tgh.2020.01.08 [doi]
PST - epublish
SO  - Transl Gastroenterol Hepatol. 2020 Oct 5;5:55. doi: 10.21037/tgh.2020.01.08. 
      eCollection 2020.